SCHEMBL1605075

SCHEMBL1605075

Clc1cc2c(NC3CCNCC3)ncnc2s1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.63
KMT2A Q03164 4/20 0.63
KDM4E B2RXH2 3/20 0.50
HTR2B P41595 1/20 0.49
CYP1A2 P05177 9/20 0.49
CLK4 Q9HAZ1 6/20 0.49
CYP2C19 P33261 6/20 0.49
CYP2D6 P10635 4/20 0.49
IRAK4 Q9NWZ3 1/20 0.49
HSD17B10 Q99714 5/20 0.45
USP2 O75604 3/20 0.45
ALDH1A1 P00352 3/20 0.45
TSHR P16473 2/20 0.45
LMNA P02545 4/20 0.44
CYP3A4 P08684 3/20 0.44
MAPT P10636 1/20 0.44
AURKA O14965 1/20 0.44
RPS6KB1 P23443 1/20 0.44
PIP4K2A P48426 1/20 0.43
HIF1A Q16665 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1604783 0.99 MEN1 (0.62) MEN1KMT2AKDM4EHTR2BCYP1A2
SCHEMBL1604052 0.79 MEN1 (0.70) MEN1KMT2AKDM4ECYP1A2CLK4
SCHEMBL29480895 0.78 MEN1 (1.00) MEN1KMT2AKDM4E
SCHEMBL16030830 0.78 MEN1 (1.00) MEN1KMT2AKDM4E
SCHEMBL5560085 0.78 HTR2B (0.52) MEN1KMT2AKDM4EHTR2BIRAK4
Hydrochloric Acid SCHEMBL16148594 0.77 MEN1 (0.98) MEN1KMT2AKDM4E
Hydrochloric Acid SCHEMBL29480891 0.77 MEN1 (0.98) MEN1KMT2AKDM4E
SCHEMBL1604780 0.74 HTR2B (0.65) MEN1KMT2AHTR2BLMNAMAPK1
SCHEMBL1604857 0.74 IRAK4 (0.53) MEN1KMT2ACYP1A2CLK4CYP2C19
SCHEMBL1604143 0.74 HTR2B (0.69) MEN1KMT2AHTR2BMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 US disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 US disclosed
EP-1797099-B1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS EPIX DELAWARE INC (US) 2010-08-11 EP disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 US disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 US disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 US disclosed
US-7612078-B2 Piperidinylamino-thieno[2,3-D] pyrimidine compounds EPIX DELAWARE, INC. (US) 2009-11-03 US disclosed
US-7612078-B2 Piperidinylamino-thieno[2,3-D] pyrimidine compounds EPIX DELAWARE, INC. (US) 2009-11-03 US disclosed
US-7612078-B2 Piperidinylamino-thieno[2,3-D] pyrimidine compounds EPIX DELAWARE, INC. (US) 2009-11-03 US disclosed
CN-101048412-A Piperidinylamino-thieno [2, 3-D ] pyrimidine compounds EPIX DELAWARE INC (US) 2007-10-03 CN disclosed
EP-1797099-A1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS Epix Delaware, Inc. (US) 2007-06-20 EP disclosed
WO-2006034511-A1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS EPIX DELAWARE, INC. (US) 2006-03-30 WO disclosed
US-20050222176-A1 Piperidinylamino-thieno[2,3-D] pyrimidine compounds TROVIS PHARMACEUTICALS, LLC 2005-10-06 US disclosed
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds PGXHEALTH, LLC 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds HTR5A, HTR3A, HTR1A MEN1 2389/4885KMT2A 4258/4885KDM4E 4569/4885
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds HTR2B, HTR3B, HTR1B MEN1 4118/4885KMT2A 3047/4885KDM4E 3109/4885
US-20050222176-A1 Piperidinylamino-thieno[2,3-D] pyrimidine compounds HTR2B, HTR3B, HTR1B MEN1 4118/4885KMT2A 3047/4885KDM4E 3109/4885
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds HTR5A, HTR3A, HTR1A MEN1 2784/4885KMT2A 4320/4885KDM4E 4614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.